TalkMed

SINGAPORE (Oct 2): RHB is maintaining its “buy” call on TalkMed with lower 69 cents target price despite seeing huge potential in stem cells as a way of treatment, particularly for cancer.

SINGAPORE (June 28): Ang Peng Tiam, the executive director and CEO of healthcare company TalkMed Group, has been given an eight-month suspension by the Court of Three Judges on the grounds of professional misconduct.

SINGAPORE (Feb 28): RHB is starting coverage of private oncology specialist TalkMed with a “buy” on substantially lower projected FY17 losses at its associates, higher share liquidity and expectations of expansion via acquisitions.